A Multicenter, Double-Blind Study on Triple Therapy with Lansoprazole, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori in Japanese Peptic Ulcer Patients
| Autor: | Kiichi Satoh, Mototsugu Kato, Kihachiro Shimizu, Tadayoshi Takemoto, Toshio Fujioka, Takashi Shimoyama, Masahiro Asaka, Shinichi Kobayashi, Hajime Kuwayama, Ken Kimura, Toshiro Sugiyama, Yoshihiro Fukuda |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Peptic Ulcer medicine.medical_specialty Lansoprazole Microbial Sensitivity Tests Gastroenterology 2-Pyridinylmethylsulfinylbenzimidazoles Drug Administration Schedule Helicobacter Infections Pharmacotherapy Double-Blind Method Clarithromycin Internal medicine Humans Multicenter Studies as Topic Medicine Omeprazole Helicobacter pylori biology business.industry Anti-ulcer Agent Amoxicillin General Medicine Middle Aged Anti-Ulcer Agents biology.organism_classification Anti-Bacterial Agents Regimen Infectious Diseases Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Helicobacter. 6:254-262 |
| ISSN: | 1523-5378 1083-4389 |
| Popis: | Background. Two triple therapies with lansoprazole (LPZ)/amoxicillin (AMPC)/clarithromycin (CAM) for eradication of Helicobacter pylori were studied in multicenter, double-blind fashion to evaluate the eradication rate of H. pylori and safety of eradiation treatment in Japanese patients with H. pylori-positive active gastric ulcers or duodenal ulcers. Methods. Patients were randomly chosen for the control treatment of LPZ 30 mg twice a day (b.i.d.; Group A-LPZ-only) or the test treatments of LPZ 30 mg plus AMPC 750 mg and CAM 200 mg b.i.d. (Group B-LAC200) and LPZ 30 mg, AMPC 750 mg and CAM 400 mg b.i.d. (Group C-LAC400). All eradication treatments lasted for a period of 7 days. Successful eradication was assessed by culture and gastric histology 1 month after completion of the ulcer treatment. Results. The eradication rates of H. pylori in the full analysis set were 0% in Group A-LPZ-only, 87.5% in Group B-LAC200 and 89.2% in Group C-LAC400 for gastric ulcer and, 4.4% in Group A-LPZ-only, 91.1% in Group B-LAC200 and 83.7% in Group C-LAC400 for duodenal ulcer. The eradication rates of Group B-LAC200 and Group C-LAC400 were 89.2% (95% CI: 84.8–93.7%) and 86.4% (95%CI: 81.5–91.3%) in total in the full analysis set, 89% (95% CI: 84.3–93.7%) and 85.3% (95%CI: 80.1–90.5%) in the per protocol set. The eradication rates in Groups B-LAC200 and group C-LAC400 were statistically significantly higher than the rate in Group A-LPZ-only for both gastric ulcer and duodenal ulcer patients (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|